Luspatercept for Lower-Risk MDS: Data From the COMMANDS Trial

Rami Komrokji, MD, summarizes data presented at ASCO 2023 from the COMMANDS trial on the role of luspatercept in lower-risk MDS.

Related Keywords

,Myelodysplastic Syndromes ,Recent Updates ,Evolving Treatment Paradigms ,Data From ,Mds ,Myelodysplastic Syndromes Recent Updates ,Treatment Evolution Myelodysplastic Syndromes ,Mds Management ,Pasco ,Asco 2023 ,2023 Asco Annual Meeting ,American Society Of Clinical Oncology ,Prognosis ,Mds Symptoms ,Mds Diagnosis ,Mds Presentations ,High Risk Mds ,Low Risk Mds ,